GlaxoSmithKline share price down 2% despite shingles vaccine boosting earnings over estimates
The pharmaceutical giant saw its Q1 earnings exceed analysts’ estimates, driven by shingles drug sales forecast at over £1 billion.
GlaxoSmithKline (GSK) recorded a great start to the new year on Wednesday, with the pharmaceutical company’s Q1 earnings exceeding analysts’ estimates, driven by strong sales growth of its shingles vaccine Shingrix.
‘We have made a strong start to 2019, which is an important year of execution for GSK, with growth in sales, operating margins and earnings per share in Q1, in line with our expectations,’ GSK CEO Emma Walmsley said.
‘Strengthening our pipeline remains our number one priority and we reported positive data for several potential new medicines in HIV and Oncology during the quarter.’
Shingrix launched back in 2017, with the vaccine becoming a major provider of growth for the drug maker in the wake of largescale restructuring at the company that saw it spin off and sell several units.
‘Shingrix has delivered another fantastic performance in the quarter,’ Walmsley told journalists on a GSK results call.
In fact, the vaccine has sold so well that GSK forecasts sales to exceed £1 billion in 2019, with it bringing in £357 million in Q1, representing a 61.5% increase over the previous quarter.
Sales of the vaccine were driven primarily by the US, but strong growth was also recorded in Canada and in Germany.
GSK results: key figures
Overall, pharmaceutical sales climbed 4% over the same period last year to £4.2 billion, while vaccines rose 23% to £1.5 billion and consumer healthcare edged 1% higher to £2 billion.
Total earnings per share doubled to 16.8p a share, with net cash flow from operations at £663 million.
GSK also declared a 19p dividend for the quarter and expects to deliver an 80p pay-out to shareholders for the full-year 2019.
Further M&A activity on the horizon for GSK
GSK will look at further inorganic growth opportunities this year, but any deals it does pursue will likely be smaller in scale to those completed in the past, with a focus on businesses in immunology, genetics and new technologies, Walmsey said on a call with reporters.
The company is also interested in cell and gene therapies for its pipeline, with the drug maker looking to improve its manufacturing operations too, she added.
The statement comes amid plans to create a consumer health joint venture with rival Pfizer, with the CEO reporting that integration is going well, with the transaction scheduled for completion in the second half of the year, subject to regulatory approval.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
See your opportunity?
Seize it now. Trade over 17,000+ markets on our award-winning platform, with low spreads on indices, shares, commodities and more.
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
